Chief Executive Officer
“I am thrilled to lead an outstanding team that shares the critical mission to truly harness the power of immunotherapy for all patients with cancer.”
David Southwell is the Chief Executive Officer of TScan and also serves as a member of the Company’s Board of Directors. Previously, David served as President and Chief Executive Officer, and member of the Board of Directors of Inotek Pharmaceuticals until Inotek merged with Rocket Pharmaceuticals. Prior to that, Mr. Southwell served as Executive Vice President, Chief Financial Officer of Human Genome Sciences, Inc. until its merger with GlaxoSmithKline plc. and as Executive Vice President and Chief Financial Officer of Sepracor Inc. and as an investment banker at Lehman Brothers. Mr. Southwell is a member of the Board of Directors of PTC Therapeutics, Inc. and has also served on the Boards of Directors of Rocket Pharmaceuticals, Human Genome Sciences Inc., THL Credit Inc., Inventiv Health, and Biosphere Medical. Mr. Southwell received a B.A. from Rice University and an M.B.A. from the Tuck School at Dartmouth College, where he has served as head of the MBA Advisory Board and currently serves on the Board of Overseers.
When he’s away from the helm at TScan, David is an avid offshore racer on his sailboat Alchemy. He competes in both singlehanded and crewed events around the world.